person · Reporting owner

COUGHLIN CHRISTOPHER J

Disclosed activity across 7 companies

Tapewire entity: 34200
SEC CIK: 0001110750

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CENTENE CORPCNC · Entity 3133	Director	September 30, 2026	September 30, 2026
DUN & BRADSTREET CORP/NWDNB · Entity 160376	Director	March 10, 2017	March 13, 2017
HOLOGIC INCHOLX · Entity 12463	Director	March 08, 2017	March 09, 2017
Prestige Consumer Healthcare Inc.PBH · Entity 4350	Director	August 02, 2022	August 03, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CENTENE CORP

Report date September 30, 2026 · Filed September 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,293.926	Reported balance After 2026-09-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 583 · Balance 19,293.926 F1: Ownership includes 3,992 shares of previously-granted restricted stock units subject to vesting requirements.
Common StockSEC Table I · non-derivative	IndirectBy Grantor Retained Annuity Trust	30,054	Reported balance Holding disclosure · report date 2026-09-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 30,054 F2: Owned by a grantor retained annuity trust for the benefit of Mr. Coughlin and his adult children, of which Mr. Coughlin is the sole trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Ownership includes 3,992 shares of previously-granted restricted stock units subject to vesting requirements.

F2: Owned by a grantor retained annuity trust for the benefit of Mr. Coughlin and his adult children, of which Mr. Coughlin is the sole trustee.

DUN & BRADSTREET CORP/NW

Report date March 10, 2017 · Filed March 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	16,535.9103	Reported balance After 2017-03-10 transaction · row 1 1 source row Row 1 · 2017-03-10 · Grant · Acquired 74.6525 · Balance 16,535.9103 F1: Acquired pursuant to a dividend reinvestment feature of the issuer's stock incentive plan in connection with restricted stock units held by the reporting person.
Phantom Stock Units - Deferred CompensationSEC Table II · derivative / convertible security	Direct	38,317.104	Reported balance After 2017-03-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-03-10 · Grant · Acquired 175.08 · Balance 38,317.104 F3: Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the "Plan"). F4: Each phantom stock unit entitles the reporting person to a cash payment based on the value on the payout date of the issuer's common stock corresponding to such units. Based on the $107.80 closing price of the issuer's common stock on the transaction date, one share of common stock corresponds to approximately 2.67 units. F5: The reporting person may transfer these phantom stock units to alternative investment funds in the Plan beginning three years from the transaction date. F6: These phantom stock units are payable in cash after the reporting person ceases to be a member of the issuer's board of directors.
Common StockSEC Table I · non-derivative	IndirectHELD BY WIFE	800	Reported balance Holding disclosure · report date 2017-03-10 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 800 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Acquired pursuant to a dividend reinvestment feature of the issuer's stock incentive plan in connection with restricted stock units held by the reporting person.

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the "Plan").

F4: Each phantom stock unit entitles the reporting person to a cash payment based on the value on the payout date of the issuer's common stock corresponding to such units. Based on the $107.80 closing price of the issuer's common stock on the transaction date, one share of common stock corresponds to approximately 2.67 units.

F5: The reporting person may transfer these phantom stock units to alternative investment funds in the Plan beginning three years from the transaction date.

F6: These phantom stock units are payable in cash after the reporting person ceases to be a member of the issuer's board of directors.

HOLOGIC INC

Report date March 08, 2017 · Filed March 09, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,633	Ending reported balance After 2017-03-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-03-08 · Exercise / conversion · Acquired 2,427 · Balance 5,427 F1: Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting. Row 2 · 2017-03-08 · Grant · Acquired 2,206 · Balance 7,633 F2: Represents RSUs which vest on the date of the 2018 Annual Meeting of Stockholders and are settled in shares of common stock. F1: Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting.
Restricted Stock Unit Award (Right To Receive)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-03-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-03-08 · Exercise / conversion · Disposed 2,427 · Balance 0 F1: Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting. F3: These RSUs vest and convert into shares of common stock on the date of the 2017 Annual Meeting of Stockholders.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.92 · Expires 2027-03-08	Direct	6,816	Reported balance After 2017-03-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-03-08 · Grant · Acquired 6,816 · Balance 6,816 F4: Options become exercisable on the date of the 2018 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting.

F2: Represents RSUs which vest on the date of the 2018 Annual Meeting of Stockholders and are settled in shares of common stock.

F3: These RSUs vest and convert into shares of common stock on the date of the 2017 Annual Meeting of Stockholders.

F4: Options become exercisable on the date of the 2018 Annual Meeting of Stockholders.

Prestige Consumer Healthcare Inc.

Report date August 02, 2022 · Filed August 03, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	13,218	Reported balance After 2022-08-02 transaction · row 1 1 source row Row 1 · 2022-08-02 · Grant · Acquired 2,495 · Balance 13,218 F1: The Reporting Person received 2,495 restricted stock units (equal to $150,000 divided by the closing stock price of $60.12on August 2, 2022) in connection with the Issuer's director compensation program. The restricted stock units vest on August 2, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person received 2,495 restricted stock units (equal to $150,000 divided by the closing stock price of $60.12on August 2, 2022) in connection with the Issuer's director compensation program. The restricted stock units vest on August 2, 2023.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALEXION PHARMACEUTICALS, INC.

Report date July 21, 2021 · Filed July 23, 2021

Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2021-07-21 transaction · row 1 1 source row Row 1 · 2021-07-21 · Disposition to issuer · Disposed 42,347 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $138.86 · Expires 2026-05-11	Direct	Reported balance After 2021-07-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-21 · Disposition to issuer · Disposed 2,294 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $167.97 · Expires 2024-07-22	Direct	Reported balance After 2021-07-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-21 · Disposition to issuer · Disposed 2,706 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $155.01 · Expires 2025-05-06	Direct	Reported balance After 2021-07-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-21 · Disposition to issuer · Disposed 2,343 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.

F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.

Allergan plc

Report date May 08, 2020 · Filed May 12, 2020

Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	IndirectBy grantor retained annuity trust	26,080	Reported balance After 2020-05-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-05-08 · Disposition to issuer · Disposed 471 · Balance 26,080 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	IndirectBy family trust	16,542	Reported balance After 2020-05-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-05-08 · Disposition to issuer · Disposed 9,538 · Balance 16,542 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	0	Reported balance After 2020-05-08 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2020-05-08 · Disposition to issuer · Disposed 16,532 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $90.22 · Expires 2023-08-14	Direct	0	Reported balance After 2020-05-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-05-08 · Disposition to issuer · Disposed 2,790 · Balance 0 F3: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F2: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $73.14 · Expires 2022-08-22	Direct	0	Reported balance After 2020-05-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-05-08 · Disposition to issuer · Disposed 3,691 · Balance 0 F3: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F2: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2021-08-22	Direct	0	Reported balance After 2020-05-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-05-08 · Disposition to issuer · Disposed 9,446 · Balance 0 F3: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F2: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

F2: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F3: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

Karuna Therapeutics, Inc.

Report date March 18, 2024 · Filed March 18, 2024

Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-03-18 transaction · row 1 1 source row Row 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.65 · Expires 2030-04-23	Direct	Reported balance After 2024-03-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-18 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15	Direct	Reported balance After 2024-03-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14	Direct	Reported balance After 2024-03-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $193.19 · Expires 2033-01-02	Direct	Reported balance After 2024-03-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-03-18 · Disposition to issuer · Disposed 976 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19	Direct	Reported balance After 2024-03-18 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F4: These Options are fully vested.

F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2026 Filed Sep 30, 2026 20:35 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	583	$0.00	$0.00	Disclosure SEC source: 0001071739-26-000180 · wk-form4_1790800525.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,293.926 F1 · balance_after: Ownership includes 3,992 shares of previously-granted restricted stock units subject to vesting requirements. Read SEC document
June 30, 2026 Filed Jul 1, 2026 21:47 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	562	$0.00	$0.00	Disclosure SEC source: 0001071739-26-000140 · wk-form4_1782942424.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,710.926 F1 · balance_after: Ownership includes 3,992 shares of restricted stock units subject to vesting requirements. Read SEC document
May 12, 2026 Filed May 13, 2026 21:17 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	3,992	$0.00	$0.00	Disclosure SEC source: 0001071739-26-000110 · wk-form4_1778707052.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,148.926 F1 · shares: This award includes 3,992 shares of restricted stock units which will vest in full on the earlier of May 12, 2027, or the date of the Registrant's next annual meeting of stockholders. Read SEC document
March 31, 2026 Filed Mar 31, 2026 22:01 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	1,140	$0.00	$0.00	Disclosure SEC source: 0001071739-26-000086 · wk-form4_1774994516.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,156.926 F1 · balance_after: Ownership includes 3,579 shares of restricted stock units subject to vesting requirements. Read SEC document
December 31, 2025 Filed Jan 5, 2026 21:55 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	729	$0.00	$0.00	Disclosure SEC source: 0001071739-26-000005 · wk-form4_1767650127.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,016.926 F1 · balance_after: Ownership includes 3,579 shares of restricted stock units subject to vesting requirements. Read SEC document
September 30, 2025 Filed Oct 1, 2025 21:46 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	852	$0.00	$0.00	Disclosure SEC source: 0001071739-25-000175 · wk-form4_1759355210.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,287.926 F1 · balance_after: Ownership includes 3,579 shares of restricted stock units subject to vesting requirements. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:58 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	556	$0.00	$0.00	Disclosure SEC source: 0001071739-25-000141 · wk-form4_1751489897.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,435.926 F1 · balance_after: Ownership includes 3,579 shares of restricted stock units subject to vesting requirements. Read SEC document
May 13, 2025 Filed May 14, 2025 21:23 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	3,579	$0.00	$0.00	Disclosure SEC source: 0001071739-25-000110 · wk-form4_1747257793.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,879.926 F1 · shares: This award includes 3,579 shares of restricted stock units which will vest in full on the earlier of May 13, 2026, or the date of the Registrant's next annual meeting of stockholders. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:07 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	500	$0.00	$0.00	Disclosure SEC source: 0001071739-25-000076 · wk-form4_1743628060.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,300.926 F1 · balance_after: Ownership includes 2,916 shares of restricted stock units subject to vesting requirements. Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:52 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	497	$0.00	$0.00	Disclosure SEC source: 0001071739-25-000007 · wk-form4_1735941166.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800.926 F1 · balance_after: Ownership includes 2,916 shares of restricted stock units subject to vesting requirements. Read SEC document
December 16, 2024 Filed Dec 18, 2024 00:33 UTC	CENTENE CORP CNC · Entity 3133	PurchaseCommon Stock	10,000	$59.44	$594,400.00	Disclosure SEC source: 0001071739-24-000227 · wk-form4_1734482019.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,357.926 F1 · price: The weighted average price for this transaction is reported within the form. Shares were purchased at prices ranging from $59.43 to $59.44. Full information regarding the number of shares at each price is available upon request. F2 · balance_after: Ownership includes 2,916 shares of restricted stock units subject to vesting requirements. Read SEC document
September 30, 2024 Filed Oct 2, 2024 21:11 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	402	$0.00	$0.00	Disclosure SEC source: 0001071739-24-000182 · wk-form4_1727903484.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,357.926 F1 · balance_after: Ownership includes 2,916 shares of restricted stock units subject to vesting requirements. Read SEC document
June 30, 2024 Filed Jul 2, 2024 21:35 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	452	$0.00	$0.00	Disclosure SEC source: 0001071739-24-000144 · wk-form4_1719956122.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,955.926 F1 · balance_after: Ownership includes 2,916 shares of restricted stock units subject to vesting requirements. Read SEC document
May 14, 2024 Filed May 16, 2024 22:13 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	2,916	$0.00	$0.00	Disclosure SEC source: 0001071739-24-000118 · wk-form4_1715897603.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,503.926 F1 · shares: This award includes 2,916 shares of restricted stock units which will vest in full on the earlier of May 14, 2025, and the date of the Registrant's next annual meeting of stockholders. Read SEC document
May 14, 2024 Filed May 24, 2024 21:28 UTC	CENTENE CORP CNC · Entity 3133	SaleCommon Stock	878	$76.75	$67,382.11	Disclosure SEC source: 0001071739-24-000128 · wk-form4_1716586116.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: Owned by family trusts, of which Mr. Coughlin serves as the sole trustee. Read SEC document
March 31, 2024 Filed Apr 2, 2024 23:36 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	388.551	$0.00	$0.00	Disclosure SEC source: 0001071739-24-000087 · wk-form4_1712101007.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,587.926 F1 · balance_after: Ownership includes 2,947 shares of restricted stock subject to vesting requirements. Read SEC document
March 18, 2024 Filed Mar 18, 2024 20:30 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Disposition to issuerOption (right to buy) · Derivative	1,904	$92.30 Strike: $237.70	$175,739.20	Disclosure SEC source: 0001140361-24-013924 · form4.xml · derivative · entry 6 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,904 shares Expires 2033-06-19 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5 · derivative.exercise_date: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. Read SEC document
March 18, 2024 Filed Mar 18, 2024 20:30 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Disposition to issuerOption (right to buy) · Derivative	976	$136.81 Strike: $193.19	$133,526.56	Disclosure SEC source: 0001140361-24-013924 · form4.xml · derivative · entry 5 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 976 shares Expires 2033-01-02 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document
March 18, 2024 Filed Mar 18, 2024 20:30 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Disposition to issuerOption (right to buy) · Derivative	5,000	$227.04 Strike: $102.96	$1,135,200.00	Disclosure SEC source: 0001140361-24-013924 · form4.xml · derivative · entry 4 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document
March 18, 2024 Filed Mar 18, 2024 20:30 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Disposition to issuerOption (right to buy) · Derivative	8,500	$201.99 Strike: $128.01	$1,716,915.00	Disclosure SEC source: 0001140361-24-013924 · form4.xml · derivative · entry 3 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document
March 18, 2024 Filed Mar 18, 2024 20:30 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Disposition to issuerOption (right to buy) · Derivative	25,000	$243.35 Strike: $86.65	$6,083,750.00	Disclosure SEC source: 0001140361-24-013924 · form4.xml · derivative · entry 2 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-04-23 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document
March 18, 2024 Filed Mar 18, 2024 20:30 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Disposition to issuerCommon Stock	990	$330.00	$326,700.00	Disclosure SEC source: 0001140361-24-013924 · form4.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2 · kind: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. F2 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. F2 · price: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. Read SEC document
December 31, 2023 Filed Jan 3, 2024 23:29 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	502.495	$0.00	$0.00	Disclosure SEC source: 0001071739-24-000007 · wk-form4_1704324553.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,199.375 F1 · balance_after: Ownership includes 2,947 shares of restricted stock subject to vesting requirements. Read SEC document
September 30, 2023 Filed Oct 3, 2023 22:51 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	544.867	$0.00	$0.00	Disclosure SEC source: 0001071739-23-000197 · wk-form4_1696373460.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,696.88 F1 · balance_after: Ownership includes 2,947 shares of restricted stock subject to vesting requirements. Read SEC document
June 30, 2023 Filed Jul 5, 2023 23:39 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	543.56	$0.00	$0.00	Disclosure SEC source: 0001071739-23-000172 · wk-form4_1688600336.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,152.013 F1 · balance_after: Ownership includes 2,947 shares of restricted stock units subject to vesting requirements. Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:11 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	1,904	$0.00 Strike: $237.70	$0.00	Disclosure SEC source: 0000950170-23-029407 · ownership.xml · derivative · entry 2 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,904 Underlying: Common Stock · 1,904 shares Expires 2033-06-19 F2 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates. Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:11 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantCommon Stock	990	$0.00	$0.00	Disclosure SEC source: 0000950170-23-029407 · ownership.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 F1 · shares: Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates. Read SEC document
May 10, 2023 Filed May 12, 2023 22:20 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	2,947	$0.00	$0.00	Disclosure SEC source: 0001071739-23-000137 · wf-form4_168393000475043.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,608.453 F1 · balance_after: Ownership includes 2,947 shares of restricted stock which will vest in full on the earlier of May 10, 2024 and the date of the Registrant's next annual meeting of stockholders. Read SEC document
March 31, 2023 Filed Apr 5, 2023 01:15 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	510.635	$0.00	$0.00	Disclosure SEC source: 0001071739-23-000100 · wf-form4_168065733150263.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,661.453 F1 · balance_after: Ownership includes 2,323 shares of restricted stock units subject to vesting requirements. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:45 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	181	$110.50 Strike: $193.19	$20,000.50	Disclosure SEC source: 0001593968-23-000080 · primary_01.xml · derivative · entry 4 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181 Underlying: Common Stock · 181 shares Expires 2033-01-02 F1 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023. F2 · derivative.exercise_date: This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:45 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	67	$111.94 Strike: $193.19	$7,499.98	Disclosure SEC source: 0001593968-23-000080 · primary_01.xml · derivative · entry 3 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67 Underlying: Common Stock · 67 shares Expires 2033-01-02 F1 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023. F2 · derivative.exercise_date: This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:45 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	407	$110.57 Strike: $193.19	$45,001.99	Disclosure SEC source: 0001593968-23-000080 · primary_01.xml · derivative · entry 2 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407 Underlying: Common Stock · 407 shares Expires 2033-01-02 F1 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023. F2 · derivative.exercise_date: This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:45 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	321	$110.41 Strike: $193.19	$35,441.61	Disclosure SEC source: 0001593968-23-000080 · primary_01.xml · derivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321 Underlying: Common Stock · 321 shares Expires 2033-01-02 F1 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023. F2 · derivative.exercise_date: This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023. Read SEC document
December 31, 2022 Filed Jan 5, 2023 00:06 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	443.805	$0.00	$0.00	Disclosure SEC source: 0001071739-23-000012 · wf-form4_167287719929148.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,150.818 F1 · balance_after: Ownership includes 2,323 shares of restricted stock units subject to vesting requirements. Read SEC document
September 30, 2022 Filed Oct 5, 2022 01:18 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	405.617	$0.00	$0.00	Disclosure SEC source: 0001071739-22-000346 · wf-form4_166493209167142.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,707.013 F1 · balance_after: Ownership includes 2,323 shares of restricted stock units subject to vesting requirements. Read SEC document
August 02, 2022 Filed Aug 3, 2022 21:19 UTC	Prestige Consumer Healthcare Inc. PBH · Entity 4350	GrantCommon Stock, par value $0.01 per share	2,495	$0.00	$0.00	Disclosure SEC source: 0001104659-22-085713 · tm2222537-5_4seq1.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,218 F1 · shares: The Reporting Person received 2,495 restricted stock units (equal to $150,000 divided by the closing stock price of $60.12on August 2, 2022) in connection with the Issuer's director compensation program. The restricted stock units vest on August 2, 2023. Read SEC document
June 30, 2022 Filed Jul 5, 2022 23:47 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	436.431	$0.00	$0.00	Disclosure SEC source: 0001071739-22-000265 · wf-form4_165706485739158.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,301.396 F1 · balance_after: Ownership includes 2,323 shares of restricted stock units subject to vesting requirements. Read SEC document
June 15, 2022 Filed Jun 16, 2022 20:31 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	5,000	$0.00 Strike: $102.96	$0.00	Disclosure SEC source: 0001593968-22-001147 · primary_01.xml · derivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders. Read SEC document
April 29, 2022 Filed May 3, 2022 23:12 UTC	CENTENE CORP CNC · Entity 3133	PurchaseCommon Stock	12,000	$81.37	$976,440.00	Disclosure SEC source: 0001071739-22-000219 · wf-form4_165161949758074.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,864.965 F1 · price: The weighted average price for this transaction is reported within the form. Shares were sold at prices ranging from $81.34 to $81.37. Full information regarding the number of shares at each price is available upon request F2 · balance_after: Ownership includes 2,323 shares of restricted stock units subject to vesting requirements. Read SEC document
April 26, 2022 Filed Apr 29, 2022 01:01 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	2,323	$0.00	$0.00	Disclosure SEC source: 0001071739-22-000199 · wf-form4_165119398351804.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,864.965 F1 · balance_after: Ownership includes 2,323 shares of restricted stock which will vest in full on the earlier of April 26, 2023 and the date of the Registrant's next annual meeting of stockholders. Read SEC document
March 31, 2022 Filed Apr 5, 2022 00:40 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	441.965	$82.02	$36,249.97	Disclosure SEC source: 0001071739-22-000148 · wf-form4_164911923713237.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541.965 F1 · balance_after: Ownership includes 1,100 shares of restricted stock units subject to vesting requirements. Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:35 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $80.57	$0.00	Disclosure SEC source: 0001071739-22-000061 · wf-form4_164445329459039.xml · derivative · entry 2 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-02-07 F2 · derivative.exercise_date: The options vest in three equal installments on the anniversary of the grant beginning on February 7, 2023. Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:35 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	1,100	$0.00	$0.00	Disclosure SEC source: 0001071739-22-000061 · wf-form4_164445329459039.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · balance_after: Ownership includes 1,100 shares of restricted stock vesting on the date of the April 2022 Annual Meeting of Stockholders. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:03 UTC	Prestige Consumer Healthcare Inc. PBH · Entity 4350	GrantCommon Stock, par value $0.01 per share	2,808	$0.00	$0.00	Disclosure SEC source: 0001104659-21-100938 · tm2124298-1_4seq1.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,723 F1 · shares: The Reporting Person received 2,808 restricted stock units (equal to $150,000 divided by the closing stock price of $53.42 on August 3, 2021) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:54 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerOption to Purchase Common Stock · Derivative	2,343	$155.01 Strike: $155.01	$363,188.43	Disclosure SEC source: 0000899866-21-000077 · wf-form4_162707363692831.xml · derivative · entry 4 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 2,343 shares Expires 2025-05-06 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:54 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerOption to Purchase Common Stock · Derivative	2,706	$167.97 Strike: $167.97	$454,526.82	Disclosure SEC source: 0000899866-21-000077 · wf-form4_162707363692831.xml · derivative · entry 3 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 2,706 shares Expires 2024-07-22 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:54 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerOption to Purchase Common Stock · Derivative	2,294	$138.86 Strike: $138.86	$318,544.84	Disclosure SEC source: 0000899866-21-000077 · wf-form4_162707363692831.xml · derivative · entry 2 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 2,294 shares Expires 2026-05-11 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:54 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerCommon Stock, par value $.0001 per share	42,347	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000077 · wf-form4_162707363692831.xml · nonDerivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. Read SEC document
June 16, 2021 Filed Jun 23, 2021 20:29 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	8,500	$0.00 Strike: $128.01	$0.00	Disclosure SEC source: 0001593968-21-001681 · primary_01.xml · derivative · entry 1 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders. Read SEC document
May 20, 2021 Filed May 24, 2021 16:36 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	729	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000047 · wf-form4_162188855020732.xml · nonDerivative · entry 2 COUGHLIN CHRISTOPHER J · CIK 0001110750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,347 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.